{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:03:15Z","timestamp":1776294195344,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant Nos.81770673"],"award-info":[{"award-number":["Grant Nos.81770673"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11255-022-03129-0","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:02:41Z","timestamp":1646038961000},"page":"737-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"54","author":[{"given":"Si-hong","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-036X","authenticated-orcid":false,"given":"De-yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"issue":"5","key":"3129_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00467-007-0691-z","volume":"23","author":"C Verpoorten","year":"2008","unstructured":"Verpoorten C, Buyse GM (2008) The neurogenic bladder: medical treatment. Pediatr Nephrol 23(5):717\u2013725. https:\/\/doi.org\/10.1007\/s00467-007-0691-z","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"3129_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12894-017-0216-4","volume":"17","author":"MJ Tijnagel","year":"2017","unstructured":"Tijnagel MJ, Scheepe JR, Blok BF (2017) Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin. BMC Urol 17(1):30. https:\/\/doi.org\/10.1186\/s12894-017-0216-4","journal-title":"BMC Urol"},{"issue":"6","key":"3129_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11934-003-0025-z","volume":"4","author":"SA MacDiarmid","year":"2003","unstructured":"MacDiarmid SA (2003) Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 4(6):446\u2013451. https:\/\/doi.org\/10.1007\/s11934-003-0025-z","journal-title":"Curr Urol Rep"},{"issue":"2","key":"3129_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1464-410X.2005.05374.x","volume":"95","author":"CRJ Woodhouse","year":"2005","unstructured":"Woodhouse CRJ (2005) Myelomeningocele in young adults. BJU Int 95(2):223\u2013230. https:\/\/doi.org\/10.1111\/j.1464-410X.2005.05374.x","journal-title":"BJU Int"},{"issue":"2","key":"3129_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2015.07.071","volume":"69","author":"J Groen","year":"2016","unstructured":"Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, Karsenty G, Kessler TM, Schneider M, Hoen L, Blok B (2016) Summary of European association of urology (EAU) guidelines on neuro-urology. Eur Urol 69(2):324\u2013333. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.071","journal-title":"Eur Urol"},{"issue":"2A Suppl","key":"3129_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0090-4295(98)90009-7","volume":"51","author":"AJ Wein","year":"1998","unstructured":"Wein AJ (1998) Pharmacologic options for the overactive bladder. Urology 51(2A Suppl):43\u201347. https:\/\/doi.org\/10.1016\/s0090-4295(98)90009-7","journal-title":"Urology"},{"key":"3129_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2021.08.011","author":"D Bishara","year":"2021","unstructured":"Bishara D, Perera G, Harwood D, Taylor D, Sauer J, Funnell N, Stewart R, Mueller C (2021) Centrally acting anticholinergic drugs used for urinary conditions associated with worse outcomes in dementia. J Am Med Dir Assoc. https:\/\/doi.org\/10.1016\/j.jamda.2021.08.011","journal-title":"J Am Med Dir Assoc"},{"issue":"8","key":"3129_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J (2019) Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 179(8):1084\u20131093. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0677","journal-title":"JAMA Intern Med"},{"issue":"7","key":"3129_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1046\/j.1464-410x.2001.02152.x","volume":"87","author":"P Ferrara","year":"2001","unstructured":"Ferrara P, D\u2019Aleo CM, Tarquini E, Salvatore S, Salvaggio E (2001) Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 87(7):674\u2013678. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02152.x","journal-title":"BJU Int"},{"issue":"2 Pt 2","key":"3129_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s0022-5347(17)36663-6","volume":"148","author":"CA Massad","year":"1992","unstructured":"Massad CA, Kogan BA, Trigo-Rocha FE (1992) The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 148(2 Pt 2):595\u2013597. https:\/\/doi.org\/10.1016\/s0022-5347(17)36663-6","journal-title":"J Urol"},{"issue":"4","key":"3129_CR11","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/s0022-5347(17)35130-3","volume":"151","author":"NG Kasabian","year":"1994","unstructured":"Kasabian NG, Vlachiotis JD, Lais A, Klumpp B, Kelly MD, Siroky MB, Bauer SB (1994) The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol 151(4):944\u2013945. https:\/\/doi.org\/10.1016\/s0022-5347(17)35130-3","journal-title":"J Urol"},{"issue":"3","key":"3129_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.juro.2008.05.056","volume":"180","author":"LA Guerra","year":"2008","unstructured":"Guerra LA, Moher D, Sampson M, Barrowman N, Pike J, Leonard M (2008) Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. J Urol 180(3):1091\u20131097. https:\/\/doi.org\/10.1016\/j.juro.2008.05.056","journal-title":"J Urol"},{"issue":"1","key":"3129_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/003655902317259319","volume":"36","author":"K Lehtoranta","year":"2002","unstructured":"Lehtoranta K, Tainio H, Lukkari-Lax E, Hakonen T, Tammela TL (2002) Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 36(1):18\u201324. https:\/\/doi.org\/10.1080\/003655902317259319","journal-title":"Scand J Urol Nephrol"},{"issue":"5","key":"3129_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/nau.22755","volume":"35","author":"A Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der A, Albrecht U, Schnitker J, Reitz A, Stein R (2016) Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. Neurourol Urodynam 35(5):582\u2013588. https:\/\/doi.org\/10.1002\/nau.22755","journal-title":"Neurourol Urodynam"},{"key":"3129_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"9","key":"3129_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"issue":"5 Pt 2","key":"3129_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1464-410x.1993.tb16255.x","volume":"72","author":"KV Prasad","year":"1993","unstructured":"Prasad KV, Vaidyanathan S (1993) Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity. Br J Urol 72(5 Pt 2):719\u2013722. https:\/\/doi.org\/10.1111\/j.1464-410x.1993.tb16255.x","journal-title":"Br J Urol"},{"issue":"6","key":"3129_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/s0022-5347(17)41304-8","volume":"141","author":"CB Brendler","year":"1989","unstructured":"Brendler CB, Radebaugh LC, Mohler JL (1989) Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 141(6):1350\u20131352. https:\/\/doi.org\/10.1016\/s0022-5347(17)41304-8","journal-title":"J Urol"},{"issue":"2","key":"3129_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/j.2048-7940.2010.tb00036.x","volume":"35","author":"M Ersoz","year":"2010","unstructured":"Ersoz M, Yildiz N, Akyuz M, Koseoglu F (2010) Efficacy of combined oral-intravesical oxybutynin hydrochloride treatment for patients with overactive detrusors and indwelling urethral catheters. Rehabil Nurs 35(2):80\u201386. https:\/\/doi.org\/10.1002\/j.2048-7940.2010.tb00036.x","journal-title":"Rehabil Nurs"},{"issue":"1","key":"3129_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/sc.1994.5","volume":"32","author":"M Mizunaga","year":"1994","unstructured":"Mizunaga M, Miyata M, Kaneko S, Yachiku S, Chiba K (1994) Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. Paraplegia 32(1):25\u201329. https:\/\/doi.org\/10.1038\/sc.1994.5","journal-title":"Paraplegia"},{"issue":"3 Pt 2","key":"3129_CR21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/00005392-199809020-00031","volume":"160","author":"G Buyse","year":"1998","unstructured":"Buyse G, Verpoorten C, Vereecken R, Casaer P (1998) Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 160(3 Pt 2):1084\u20131087. https:\/\/doi.org\/10.1097\/00005392-199809020-00031","journal-title":"J Urol"},{"issue":"6","key":"3129_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jpurol.2007.05.007","volume":"3","author":"A Hayashi","year":"2007","unstructured":"Hayashi A, Saito M, Okada S, Hanada T, Watanabe T, Satoh K, Kanzaki S (2007) Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children. J Pediatr Urol 3(6):438\u2013442. https:\/\/doi.org\/10.1016\/j.jpurol.2007.05.007","journal-title":"J Pediatr Urol"},{"issue":"2 Pt 2","key":"3129_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/00005392-199608001-00053","volume":"156","author":"R Kaplinsky","year":"1996","unstructured":"Kaplinsky R, Greenfield S, Wan J, Fera M (1996) Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J Urol 156(2 Pt 2):753\u2013756. https:\/\/doi.org\/10.1097\/00005392-199608001-00053","journal-title":"J Urol"},{"issue":"3","key":"3129_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/s0090-4295(99)00540-3","volume":"55","author":"J Pannek","year":"2000","unstructured":"Pannek J, Sommerfeld HJ, B\u00f6tel U, Senge T (2000) Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 55(3):358\u2013362. https:\/\/doi.org\/10.1016\/s0090-4295(99)00540-3","journal-title":"Urology"},{"issue":"8","key":"3129_CR25","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1442-2042.2004.00871.x","volume":"11","author":"M Saito","year":"2004","unstructured":"Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I (2004) Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol 11(8):592\u2013596. https:\/\/doi.org\/10.1111\/j.1442-2042.2004.00871.x","journal-title":"Int J Urol"},{"issue":"5","key":"3129_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sc.1996.51","volume":"34","author":"SM Szollar","year":"1996","unstructured":"Szollar SM, Lee SM (1996) Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 34(5):284\u2013287. https:\/\/doi.org\/10.1038\/sc.1996.51","journal-title":"Spinal Cord"},{"issue":"4","key":"3129_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1159\/000475078","volume":"28","author":"H Madersbacher","year":"1995","unstructured":"Madersbacher H, Knoll M (1995) Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results. Eur Urol 28(4):340\u2013344. https:\/\/doi.org\/10.1159\/000475078","journal-title":"Eur Urol"},{"issue":"6","key":"3129_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1464-410X.2008.08093.x","volume":"103","author":"H Madersbacher","year":"2009","unstructured":"Madersbacher H, M\u00fcrtz G, Alloussi S, Domurath B, Henne T, K\u00f6rner I, Niedeggen A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G (2009) Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int 103(6):776\u2013781. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.08093.x","journal-title":"BJU Int"},{"issue":"4","key":"3129_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/nau.22560","volume":"34","author":"M Humblet","year":"2015","unstructured":"Humblet M, Verpoorten C, Christiaens MH, Hirche H, Jansen K, Buyse G, van Gool JD (2015) Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn 34(4):336\u2013342. https:\/\/doi.org\/10.1002\/nau.22560","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"3129_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.sc.3100573","volume":"36","author":"S Vaidyananthan","year":"1998","unstructured":"Vaidyananthan S, Soni BM, Brown E, Sett P, Krishnan KR, Bingley J, Markey S (1998) Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction. Spinal Cord 36(6):409\u2013414. https:\/\/doi.org\/10.1038\/sj.sc.3100573","journal-title":"Spinal Cord"},{"issue":"5","key":"3129_CR31","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1097\/01.ju.0000049903.60057.4b","volume":"169","author":"S De Wachter","year":"2003","unstructured":"De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169(5):1892\u20131895. https:\/\/doi.org\/10.1097\/01.ju.0000049903.60057.4b","journal-title":"J Urol"},{"issue":"8","key":"3129_CR32","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/nau.24778","volume":"40","author":"KA Softness","year":"2021","unstructured":"Softness KA, Thaker H, Theva D, Rajender A, Cilento BG Jr, Bauer SB (2021) Onabotulinumtoxin A (Botox): a reasonable alternative for refractory neurogenic bladder dysfunction in children and young adults. Neurourol Urodyn 40(8):1981\u20131988. https:\/\/doi.org\/10.1002\/nau.24778","journal-title":"Neurourol Urodyn"},{"key":"3129_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18168743","author":"H Shabir","year":"2021","unstructured":"Shabir H, Hashemi S, Al-Rufayie M, Adelowo T, Riaz U, Ullah U, Alam B, Anwar M, de Preux L (2021) Cost-utility analysis of oxybutynin vs onabotulinumtoxin A (Botox) in the treatment of overactive bladder syndrome. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph18168743","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"3129_CR34","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1046\/j.1464-410x.1998.00888.x","volume":"82","author":"P Amark","year":"1998","unstructured":"Amark P, Eksborg S, Juneskans O, Bussman G, Palm C (1998) Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. Br J Urol 82(6):859\u2013864. https:\/\/doi.org\/10.1046\/j.1464-410x.1998.00888.x","journal-title":"Br J Urol"},{"issue":"4","key":"3129_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/sj.sc.3100995","volume":"38","author":"A Haferkamp","year":"2000","unstructured":"Haferkamp A, Staehler G, Gerner HJ, D\u00f6rsam J (2000) Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 38(4):250\u2013254. https:\/\/doi.org\/10.1038\/sj.sc.3100995","journal-title":"Spinal Cord"},{"issue":"6","key":"3129_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/0090-4295(93)90098-u","volume":"41","author":"DL Weese","year":"1993","unstructured":"Weese DL, Roskamp DA, Leach GE, Zimmern PE (1993) Intravesical oxybVnin chloride: experience with 42 patients. Urology 41(6):527\u2013530. https:\/\/doi.org\/10.1016\/0090-4295(93)90098-u","journal-title":"Urology"},{"issue":"7119","key":"3129_CR37","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/bmj.315.7119.1363","volume":"315","author":"CA Donnellan","year":"1997","unstructured":"Donnellan CA, Fook L, McDonald P, Playfer JR (1997) Oxybutynin and cognitive dysfunction. BMJ 315(7119):1363\u20131364. https:\/\/doi.org\/10.1136\/bmj.315.7119.1363","journal-title":"BMJ"},{"issue":"3","key":"3129_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jpeds.2009.01.074","volume":"155","author":"P Gish","year":"2009","unstructured":"Gish P, Mosholder AD, Truffa M, Johann-Liang R (2009) Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. J Pediatr 155(3):432\u2013434. https:\/\/doi.org\/10.1016\/j.jpeds.2009.01.074","journal-title":"J Pediatr"},{"issue":"4","key":"3129_CR39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","volume":"73","author":"AK Nambiar","year":"2018","unstructured":"Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, Bedretdinova DA, Amb\u00fchl D, Farag F, Lombardo R, Schneider MP, Burkhard FC (2018) EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 73(4):596\u2013609. https:\/\/doi.org\/10.1016\/j.eururo.2017.12.031","journal-title":"Eur Urol"},{"issue":"11","key":"3129_CR40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","volume":"18","author":"B Welk","year":"2021","unstructured":"Welk B, Richardson K, Panicker JN (2021) The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol 18(11):686\u2013700. https:\/\/doi.org\/10.1038\/s41585-021-00504-x","journal-title":"Nat Rev Urol"},{"issue":"4","key":"3129_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/nau.20507","volume":"27","author":"KM Giramonti","year":"2008","unstructured":"Giramonti KM, Kogan BA, Halpern LF (2008) The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn 27(4):315\u2013318. https:\/\/doi.org\/10.1002\/nau.20507","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"3129_CR42","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.juro.2013.06.036","volume":"190","author":"PW Veenboer","year":"2013","unstructured":"Veenboer PW, Huisman J, Chrzan RJ, Kuijper CF, Dik P, de Kort LM, de Jong TP (2013) Behavioral effects of long-term antimuscarinic use in patients with spinal dysraphism: a case control study. J Urol 190(6):2228\u20132232. https:\/\/doi.org\/10.1016\/j.juro.2013.06.036","journal-title":"J Urol"},{"issue":"7","key":"3129_CR43","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s004310100741","volume":"160","author":"JD van Gool","year":"2001","unstructured":"van Gool JD, Dik P, de Jong TP (2001) Bladder-sphincter dysfunction in myelomeningocele. Eur J Pediatr 160(7):414\u2013420. https:\/\/doi.org\/10.1007\/s004310100741","journal-title":"Eur J Pediatr"},{"issue":"1","key":"3129_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1542\/peds.84.1.78","volume":"84","author":"DB Joseph","year":"1989","unstructured":"Joseph DB, Bauer SB, Colodny AH, Mandell J, Retik AB (1989) Clean, intermittent catheterization of infants with neurogenic bladder. Pediatrics 84(1):78\u201382","journal-title":"Pediatrics"},{"issue":"6","key":"3129_CR45","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0022-5347(01)65430-2","volume":"156","author":"RS Sutherland","year":"1996","unstructured":"Sutherland RS, Kogan BA, Baskin LS, Mevorach RA (1996) Clean intermittent catheterization in boys using the LoFric catheter. J Urol 156(6):2041\u20132043","journal-title":"J Urol"},{"issue":"Suppl 1","key":"3129_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000282246","volume":"47","author":"K Kato","year":"1991","unstructured":"Kato K, Kondo A, Saito M, Miyake K, Wein AJ, Levin RM (1991) In vitro intravesical instillation of anticholinergic, antispasmodic and calcium blocking agents to decrease bladder contractility. Urol Int 47(Suppl 1):36\u201338. https:\/\/doi.org\/10.1159\/000282246","journal-title":"Urol Int"},{"issue":"4","key":"3129_CR47","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0022-5347(01)65629-5","volume":"156","author":"KA Painter","year":"1996","unstructured":"Painter KA, Vates TS, Bukowski TP, Fleming P, Freedman AL, Smith CA, Gonzalez R, Perlmutter AD (1996) Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. J Urol 156(4):1459\u20131462","journal-title":"J Urol"},{"issue":"3","key":"3129_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/nau.10066","volume":"21","author":"W Sch\u00e4fer","year":"2002","unstructured":"Sch\u00e4fer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21(3):261\u2013274. https:\/\/doi.org\/10.1002\/nau.10066","journal-title":"Neurourol Urodyn"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03129-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03129-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03129-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T12:21:55Z","timestamp":1647346915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03129-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3129"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03129-0","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"11 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing economic interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}